Loading...

Invitae Corporation

NVTA•NYSE
Healthcare
Medical - Diagnostics & Research
$0.02
$-0.01(-35.59%)

Invitae Corporation (NVTA) Stock Overview

Explore Invitae Corporation’s financial performance, market position, analyst ratings, and future outlook.

Stats data is not available for NVTAStats details for NVTA are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for NVTAAnalyst Recommendations details for NVTA are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.

CEO

Mr. Kenneth D. Knight

Employees

1,700

Headquarters

1400 16th Street, San Francisco, CA

Founded

2015

Frequently Asked Questions